Trial reportCell reports. Medicine2025
A sequential dual-site repetitive transcranial magnetic stimulation for major depressive disorder: A randomized clinical trial.
Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Subcallosal cingulate functional connectivity in depression: a systematic review of brain stimulation-induced changes and pretreatment connectivity predictors.Translational psychiatry · 2026Pooled it
- The Genoeconomics of Impulsive Intertemporal Choice: A Critical Review.Journal of the experimental analysis of behavior · 2026Review
- Effect of Transcranial Magnetic Stimulation in Patients with Postherpetic Neuralgia and Comorbid Depression: A Randomized Controlled Trial.Pain and therapy · 2026Article
- Repetitive transcranial magnetic stimulation is associated with improved functional recovery and time-dependent changes in apoptosis-related execution-phase markers after spinal cord injury.Scientific reports · 2026Article
- The Relationship Between Emotion Processing Assessed by an Affect Rating Task and Depression Symptoms Following the Accelerated Sequential Dorsolateral-Dorsomedial Prefrontal rTMS Treatment.Behavioral sciences (Basel, Switzerland) · 2026Article
- Clinical efficacy and safety of sequential accelerated theta burst stimulation for suicidal ideation in adults with major depressive disorder: study protocol of a randomized controlled trial.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Repetitive transcranial magnetic stimulation (rTMS) is approved for major depressive disorder (MDD), but it is limited by variable efficacy. Here, we examine antidepressant effects of our sequential dorsolateral prefrontal cortex (dlPFC)-dorsomedial prefrontal cortex (dmPFC) accelerated rTMS protocol, which includes a 4-day treatment with 4 sessions per day. At week 4, the Montgomery-Åsberg Depression Rating Scale (MADRS) reduction is significantly larger in the active group, and critical, significant differences were apparent on day 4. For active and sham-controlled groups, respectively, response rates are 57.69% and 23.08%, and remission rates are 38.46% and 15.38%. Of responders, over 85% remain in remission over 6 months. Resting-state fMRI shows dissociable symptom improvement associated with increased dlPFC-frontoparietal and decreased dmPFC-amygdalo-subcallosal cingulate functional connectivity. We highlight a cost-efficient generalizable rTMS approach targeting differential networks in MDD, which shows rapid and sustained antidepressant effects with a relatively small number of pulses and minimal treatment duration. The study is registered with ChiCTR (ChiCTR2100046042).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.